Document:

Execution
Copy

    

     

    EMPLOYMENT
AGREEMENT

     

    THIS EMPLOYMENT AGREEMENT (“Agreement”) is made
this 16th day of March, 2009 by and between NeoGenomics, Inc. a Nevada
corporation (“NeoGenomics" or the
“Employer” and
collectively with any entity that is wholly or partially owned by NeoGenomics,
the “Company”), located at 12701 Commonwealth Drive, Suite #5, Fort Myers,
Florida 33913 and Douglas M. VanOort (“Executive”), an
individual who resides at 3275 Regatta Road, Naples, FL 34103.

    

    RECITALS:

    

    WHEREAS, the Company is
engaged in the business of providing genetic and molecular diagnostic testing
services to doctors, hospitals and other healthcare institutions;
and

    

    WHEREAS, the Executive was
appointed to the Board of Directors of NeoGenomics (the “Board”) and elected as
the Chairman of the Board as of the date of this Agreement; and

    

    WHEREAS, NeoGenomics desires
to employ Executive as an officer in the capacity of Executive Chairman and
Interim Chief Executive Officer, and Executive desires to be employed by
NeoGenomics in such capacity, in accordance with the terms, covenants, and
conditions as set forth in this Agreement.

    

    NOW, THEREFORE, in
consideration of the mutual promises set forth herein and other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Employer and Executive agree as follows:

    

    1.           Employment
Period.  Subject to the terms and conditions set forth herein
and unless sooner terminated as hereinafter provided, NeoGenomics shall employ
Executive as an officer, and Executive agrees to serve as an officer and accepts
such employment for a four-year period, beginning on March 16, 2009 (the “Effective Date”) and
ending on the 4th
anniversary of the Effective Date (the “Initial Employment
Term”).  After the Initial Employment Term, this Agreement
shall automatically renew for consecutive one year periods (“renewal term”),
unless a written notice of a party’s intention to terminate this Agreement at
the expiration of the Initial Employment Term (or any renewal term) is delivered
by either party at least three (3) months prior to the expiration of the Initial
Employment Term or any renewal term, as applicable.  For purposes of
this Agreement, the period from the Effective Date until the termination of the
Executive’s employment shall hereinafter be referred to as the “Term”.  Executive’s
employment pursuant to this Agreement shall be “at will” as such term is
construed under Florida law.

    

    2.           Title and
Duties.  During the Term, NeoGenomics shall employ Executive in
the capacity of Executive Chairman.  In addition, during the period
from the Effective Date until the time that NeoGenomics hires a full-time Chief
Executive Officer (“CEO”), NeoGenomics
shall additionally employ Executive in the capacity of Interim CEO (such period
hereinafter referred to as the “CEO
Period”).  Executive accepts employment in these
capacities.  Executive will report to and be subject to the general
supervision and direction of the Board.  If requested, Executive will
serve in similar capacities for each or any subsidiary of NeoGenomics without
additional compensation.  Executive shall perform such duties as are
customarily performed by someone holding the title of Executive Chairman and/or
Interim CEO in the same or similar businesses or enterprises as that engaged in
by the Company and such other duties as the Board may assign from time to
time.

    

    3.           Compensation
and Benefits of Executive.  The Company shall compensate
Executive for Executive's services rendered under this Agreement as
follows:

    
       

       

      
        
          	 	      
                  Executive
      Initials

                
	 	 
	 	 
	 	
                  ____________

                

        

      

       

    

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

    
      Execution
Copy

    
      	
               
      

            	
              a.

            	
              Base
      Salary.  Unless otherwise adjusted by the Compensation
      Committee of the Board (the “Compensation Committee”), the Company shall
      pay Executive a Core Base Salary and an Incremental CEO Base Salary (as
      such terms are defined below, and collectively referred to as the “Base Salary”),
      payable in equal installments at such times as is consistent with normal
      Company payroll policy, according to the following
  amounts:

            

    

    

    
      	
               
      

            	
              1.)  A
      base salary equating to two hundred twenty five thousand dollars
      ($225,000) per annum (the “Core Base
      Salary”) until the end of the Term or until such time that the
      Executive desires to reduce his work time commitment to the Company to
      less than 2.5 days per week, in which case the Board and Executive will
      work in good faith to determine a new Core Base Salary that is
      appropriate.

            

    

    

    
      	
               
      

            	
              2.)  During
      the CEO Period and so long as Executive is able to spend at least one (1)
      additional day per week on average on the Company’s affairs (for a total
      of 3.5 days/week on average), the Company agrees to pay an additional
      amount in base salary (the “Incremental CEO Base
      Salary”) equal to $50,000 per annum.  In the event that
      the Executive is unable to dedicate a least 3.5 days/week on average on
      the affairs of the Company, the Board and the Executive agree to work in
      good faith to determine a new Incremental CEO Base Salary that is
      appropriate.

            

    

    

    
      	
               
      

            	
              b.

            	
              Bonus.  Executive
      will be eligible for an annual cash bonus based on
      performance.  The amount of such bonus shall be based on the
      available resources of the Company and shall be at the discretion of the
      Compensation Committee; provided, however, if the Company’s actual
      performance in any given fiscal year meets or exceeds the below listed
      annual performance goals for such fiscal year, the Executive shall be
      entitled to the cash bonuses outlined below for such fiscal
      year.  The Company agrees that such cash bonus, if any, will be
      paid no later than ninety (90) days after the end of the fiscal year to
      which it applied.

            

    

    

    
      	
               
      

            	
              1.)  For
      any given fiscal year during the Term, if the Company’s actual
      consolidated revenue for such fiscal year, after excluding the effects of
      any Revenue Exclusions (as defined in Section 3e(1) below), exceeds the
      annual revenue goals approved by the Board for such fiscal year based on
      the Board-approved Company budget for such year, Executive shall be
      entitled to a cash bonus of at least fifteen percent (15%) of his Base
      Salary as such Base Salary was in effect as of the end of such fiscal
      year; and

            

    

    

    
      	
               
      

            	
              2.)  For
      any given fiscal year during the Term, if the Company’s actual Adjusted
      EBITDA (as defined below) after excluding the effects of any Adjusted
      EBITDA Exclusions (as defined in Section 3e(2) below), exceeds the annual
      goals for Adjusted EBITDA approved by the Board for such fiscal year based
      on the Board-approved Company budget for such year, Executive shall be
      entitled to a cash bonus of at least fifteen percent (15%) of his Base
      Salary as such Base Salary was in effect as of the end of such fiscal
      year.  For the purposes of this Agreement, “Adjusted
      EBITDA” is defined as consolidated GAAP earnings before interest,
      taxes, depreciation, amortization, and non-cash stock based compensation
      expenses.  In addition, any extraordinary or non-recurring
      actual expenses incurred by the Company that were not included in the
      budget for the applicable fiscal year that in the reasonable judgment of
      the Compensation Committee could not have been foreseen by the Company’s
      management during the process to set the budget for such year may, at the
      Board’s discretion, also be added back to the total when calculating
      actual Adjusted EBITDA for such fiscal
year.

            

    

    
       

       

      
        
          	 	      
                  Executive
      Initials

                
	 	 
	 	 
	 	
                  ____________

                

        

      

       

    

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    Execution
Copy

    
 

    
      	
               
      

            	
              c.

            	
              Benefits.  Subject
      to the eligibility requirements (including, but not limited to,
      participation by part-time employees), and enrollment provisions of the
      Company’s employee benefit plans, Executive may, to the extent he so
      chooses, participate in any and all of the Company’s employee benefit
      plans, at the Company’s expense.  All Company benefits are
      identified in the Employee Handbook and are subject to change without
      notice or explanation.  In addition, subject to the eligibility
      requirements (including, but not limited to, participation by a part-time
      employee) and enrollment provisions of the Company’s executive benefit
      programs, Executive shall also be entitled to participate in any and all
      other benefits programs established for officers of the
      Company.

            

    

    

    
      	
               
      

            	
              d.

            	
              Stock
      Options.  On the Effective Date, Executive will be
      granted an option to purchase 1,000,000 shares of the Company’s common
      stock (the “Options”) on
      the terms and conditions listed below.  Such Options will have a
      strike price equal to the fair market value of the common stock as of the
      Effective Date, which pursuant to NeoGenomics’ Amended and Restated Equity
      Incentive Plan (the “Plan”), shall be equal to the closing price per share
      of NeoGenomics’ common stock on the last trading day immediately preceding
      the Effective Date.  The vesting provisions of such Options
      shall be as outlined below.  These Options shall be treated as
      incentive stock options (ISOs) to the maximum extent permitted under
      applicable law, and the remainder of the Options, if any, shall be treated
      as non-qualified stock options.  The grant of these Options will
      be made pursuant to the Company’s Plan and will be evidenced by a separate
      “Option
      Agreement” to be executed by the Company and Executive, which will
      contain all the terms and conditions of the Options (including, but not
      limited to, the provisions set forth in this Section 3(d)).  So
      long as Executive remains employed by the Company, such Options will have
      a seven-year term before
expiration.

            

    

    

    
      1.) 
Time-based
Options - 500,000 of such options will be time-based options and will
vest according to the following schedule:

    

    

    
      	
               
      

            	
              200,000

            	
              will
      vest on the first anniversary of the Effective Date; provided, however,
      that if the Executive’s employment hereunder is terminated by the Employer
      without “cause” (as such term is defined in the Option Agreement) at any
      time prior to the first anniversary of the Effective Date, then the pro
      rata portion of these 200,000 Options up until the date of termination,
      shall be deemed vested; and

            

    

     

    
      	
               
      

            	
              12,500

            	
              will
      vest each month beginning on the 13th
      monthly anniversary of the Effective Date and continuing on each monthly
      anniversary thereafter until the second anniversary of the Effective Date;
      and

            

    

     

    
      	
               
      

            	
              8,000

            	
              will
      vest each month beginning on the 25th
      monthly anniversary of the Effective Date and continuing on each monthly
      anniversary thereafter until the third anniversary of the Effective Date;
      and

            

    

     

    
      	
               
      

            	
              4,500

            	
              will
      vest each month beginning on the 37th
      monthly anniversary of the Effective Date and continuing on each monthly
      anniversary thereafter until the fourth anniversary of the Effective
      Date.

            

    

    

    
      2.)   Performance-based
Options - 500,000 of such options will be performance-based options and
will vest according to the following schedule.  Executive understands
and acknowledges that if the performance metrics for any given year are not met,
then such options shall be forfeited and the Board is under no obligation to
replenish such options.

    

    
       

       

      
        
          	 	      
                  Executive
      Initials

                
	 	 
	 	 
	 	
                  ____________

                

        

      

       

    

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    Execution
Copy

     

     

    
      	
               
      

            	
              100,000

            	
              will
      vest if the Company’s actual consolidated revenue for FY 2009, after
      excluding the effects of any Revenue Exclusions for such fiscal year,
      meets or exceeds the consolidated revenue goal established by the Board
      for the vesting of performance options, which goal will be based on the
      Company’s Board approved budget for such fiscal year;
  and

            

    

     

    
      	
               
      

            	
              100,000

            	
              will
      vest if the Company’s actual Adjusted EBITDA for FY 2009, after excluding
      the effects of any Adjusted EBITDA Exclusions for such fiscal year, meets
      or exceeds the Adjusted EBITDA goal established by the Board for the
      vesting of performance options, which will be based on the Company’s
      Board-approved budget for such fiscal year;
and

            

    

     

    
      	
               
      

            	
              75,000

            	
              will
      vest if the Company’s actual consolidated revenue for FY 2010, after
      excluding the effects of any Revenue Exclusions for such fiscal year,
      meets or exceeds the consolidated revenue goal established by the Board
      for the vesting of performance options, which goal will be based on the
      Company’s Board approved budget for such fiscal year;
  and

            

    

     

    
      	
               
      

            	
              75,000

            	
              will
      vest if the Company’s actual Adjusted EBITDA for FY 2010, after excluding
      the effects of any Adjusted EBITDA Exclusions for such fiscal year, meets
      or exceeds the Adjusted EBITDA goal established by the Board for the
      vesting of performance options, which will be based on the Company’s
      Board-approved budget for such fiscal year;
and

            

    

     

    
      	
               
      

            	
              50,000

            	
              will
      vest if the Company’s actual consolidated revenue for FY 2011, after
      excluding the effects of any Revenue Exclusions for such fiscal year,
      meets or exceeds the consolidated revenue goal established by the Board
      for the vesting of performance options, which goal will be based on the
      Company’s Board approved budget for such fiscal year;
  and

            

    

     

    
      	
               
      

            	
              50,000

            	
              will
      vest if the Company’s actual Adjusted EBITDA for FY 2011, after excluding
      the effects of any Adjusted EBITDA Exclusions for such fiscal year, meets
      or exceeds the Adjusted EBITDA goal established by the Board for the
      vesting of performance options, which will be based on the Company’s
      Board-approved budget for such fiscal year;
and

            

    

     

    
      	
               
      

            	
              25,000

            	
              will
      vest if the Company’s actual consolidated revenue for FY 2012, after
      excluding the effects of any Revenue Exclusions for such fiscal year,
      meets or exceeds the consolidated revenue goal established by the Board
      for the vesting of performance options, which goal will be based on the
      Company’s Board approved budget for such fiscal year;
  and

            

    

     

    
      	
               
      

            	
              25,000

            	
              will
      vest if the Company’s actual Adjusted EBITDA for FY 2012, after excluding
      the effects of any Adjusted EBITDA Exclusions for such fiscal year, meets
      or exceeds the Adjusted EBITDA goal established by the Board for the
      vesting of performance options, which will be based on the Company’s
      Board-approved budget for such fiscal
year.

            

    

     

    
      	
               
      

            	
              Executive
      understands that, pursuant to the Plan, upon termination of his
      employment, he will only have ninety (90) days to exercise any vested
      portion of the Options.  All Options awarded pursuant to this
      Section 3(d) will contain a provision in the Option Agreement that allows
      for immediate vesting of any unvested portion of the Options in the event
      of a change of control of
NeoGenomics.

            

    

     

    
       

      
        
          	 	      
                  Executive
      Initials

                
	 	 
	 	 
	 	
                  ____________

                

        

      

       

    

    
      
         

      

      
        4

        
          

        

      

      
         

      

      
        Execution
Copy

         

         

      

    

    
      	
               
      

            	
              e.

            	
              Revenue
      and Adjusted EBITDA Exclusions Defined.  For the purposes
      of Section 3b and 3d above, to the extent the Company acquires any
      companies or businesses during any given fiscal year and the financial
      impact of such acquisition was not previously factored into the annual
      operating budget approved by the Board, the following revenue and Adjusted
      EBITDA adjustments shall be made to the Company’s fiscal results in
      measuring whether or not the Company has met or exceeded the specific
      performance targets outlined in Sections  3b or 3d
      hereof.

            

    

    

    
      	
               
      

            	
              1.)  “Revenue
      Exclusions” shall be defined as the prorated annualized quarterly
      GAAP revenue of any company or business acquired by the Company for the
      most recent full fiscal quarter prior to the date such company or business
      is acquired by the Company.  Such annualized quarterly revenue
      shall be prorated by multiplying the total annualized quarterly revenue
      described above by a fraction, the numerator of which is the number of
      days that the financial results of the acquired business or company are
      included in the Company’s financial results during the fiscal year in
      question, and the denominator of which is
365.

            

    

    

    
      	
               
      

            	
              2.)  “Adjusted EBITDA
      Exclusions” shall be defined as the prorated annualized quarterly
      Adjusted EBITDA of any company or business acquired by the Company for the
      most recent full fiscal quarter prior to the date such company or business
      is acquired by the Company.  Such annualized quarterly Adjusted
      EBITDA shall be prorated by multiplying the total annualized quarterly
      Adjusted EBITDA described above by a fraction, the numerator of which is
      the number of days that the financial results of the acquired business or
      company are included in the Company’s financial results during the fiscal
      year in question, and the denominator of which is 365.  The
      Board, at its discretion, may add back any non-recurring or one time
      charges that may have been included in the most recent full fiscal quarter
      of the company or business being acquired when determining the appropriate
      Adjusted EBITDA for such business or
company.

            

    

    

    
      	
               
      

            	
              f.

            	
              Paid
      Time-Off and Holidays.  Executive’s paid time-off (“PTO”) and
      holidays shall be consistent with the standards set forth in the Company’s
      Employee Handbook, as revised from time to time or as otherwise published
      by the Company.  Notwithstanding the previous sentence,
      Executive will be eligible for one hundred twenty (120) hours of PTO/year,
      which will accrue on a pro-rata basis throughout the year, provided,
      however, that it is the Company’s policy that no more than forty (40)
      hours of PTO can be accrued beyond this annual limit for any employee at
      any time.  Thus, when accrued PTO reaches one hundred sixty
      (160) hours, Executive will cease accruing PTO until accrued PTO is one
      hundred twenty (120) hours or less, at which point Executive will again
      accrue PTO until he reaches one hundred sixty (160) hours.  In
      addition to PTO, there are also six (6) paid national holidays and one (1)
      “floater” day available to Company employees.  Executive agrees
      to schedule such PTO so that it minimally interferes with the Company’s
      operations.   Such PTO does not include Board excused
      absences.

            

    

    

    
      	
               
      

            	
              g.

            	
              Reimbursement
      of Normal Business Expenses.  The Company will reimburse
      all reasonable business expenses of Executive, including, but not limited
      to, cell phone expenses and business related travel, meals and
      entertainment expenses in accordance with the Company’s polices for such
      reimbursement.

            

    

    

    4.           Best
Efforts of the Executive and Minimum Time Commitments of Employment. Executive agrees to
perform all of the duties pursuant to the express and implicit terms of this
Agreement to the reasonable satisfaction of the Employer.  Executive
further agrees to perform such duties faithfully and to the best of his ability,
talent, and experience and, unless otherwise agreed to with the Company in
writing, to render such duties at least in the minimum amounts of time specified
below:

     

    
       

      
        
          	 	      
                  Executive
      Initials

                
	 	 
	 	 
	 	
                  ____________

                

        

      

       

    

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    
      Execution
Copy

    
      	
               
      

            	
              a.

            	
              So
      long as the Executive and the Board have not agreed to adjust downward the
      Executive’s Core Base Salary specified in Section 3(a), Executive agrees
      that during the Term, except for those weeks where he is on PTO, he will
      spend at least two and one-half (2.5) days/week on average on the
      Company’s business (such period as may be adjusted, the “Minimum Weekly Time
      Commitment”).   Executive further agrees that he
      will use commercially reasonable efforts to ensure that except for those
      weeks where he is on PTO, he will work at least two (2) days on average
      either at the Company’s primary place of business in Fort Myers, FL or at
      such other place or places as the interests, needs, business, or
      opportunities of the Employer shall require and/or such other place as may
      be mutually agreed upon in writing by the parties (such period as may be
      adjusted, the “On-Site/Business
      Travel Time Commitment”).

            

    

    

    
      	
               
      

            	
              b.

            	
              Notwithstanding
      the forgoing, Executives agrees that during the CEO Period, the Minimum
      Weekly Time Commitment shall be increased to three and one-half (3.5) days
      and the On-Site/Business Travel Time Commitment shall be increased to
      three (3) days.

            

    

    

    5.           Termination.  Either
party may terminate Executive’s employment with the Company at any time upon
giving sixty (60) days advance written notice to the other party. Executive
agrees that in order to help facilitate an orderly transition of authority,
unless otherwise agreed to by the parties, during such sixty (60) day notice
period no more than two weeks of unused PTO may be utilized.   In
the event of the death of Executive, the employment of Executive shall
automatically terminate on the date of Executive's death.  Within 30
days following the date Executive’s employment terminates, the Company shall pay
to Executive (or Executive’s estate if applicable) (a) the Executive’s accrued
but unpaid Base Salary through the date of termination, (b) any bonus earned by,
but not yet paid to, Executive from the prior fiscal year, (c) an amount equal
to the reasonable business expenses incurred by Executive (in accordance with
Company policy), but not yet reimbursed, prior to the termination date, and (d)
other benefits due and owing to Executive through the termination
date.

    

    6.           Confidentiality,
Non-Compete & Non-Solicitation Agreement.  Executive agrees
to the terms of the Confidentiality, Non-Solicitation and Non-Compete Agreement
attached hereto as Addendum A and has
signed that Agreement.  Such Confidentiality, Non-Solicitation and
Non-Compete Agreement is hereby incorporated into and made a part of this
Agreement.

    

    7.           Importance
of Certain Clauses.  Executive and Employer agree that the
covenants contained in the Confidentiality, Non-Solicitation and Non-Compete
Agreement attached hereto and incorporated into this Agreement are material
terms of this Agreement and all parties understand the importance of such
provisions to the ongoing business of the Employer.  As such, because
the Employer's continued business and viability depend on the protection of such
secrets and non-competition, these clauses are interpreted by the parties to
have the widest and most expansive applicability as may be allowed by law and
Executive understands and acknowledges his or her understanding of
same.

    

    8.           Consideration.  Executive
acknowledges and agrees that the provision of employment under this Agreement
and the execution by the Employer of this Agreement constitute full, adequate
and sufficient consideration to Executive for the Executive's duties,
obligations and covenants under this Agreement and under the Confidentiality,
Non-Solicitation and Non-Compete Agreement incorporated into this
Agreement.

    

    9.           Acknowledgement
of Post Termination Obligations.  Upon the effective date of
termination of Executive’s employment (unless due to Executive’s death), if
requested by the Employer, Executive shall participate in an exit interview with
the Employer and certify in writing that Executive has complied with his
contractual obligations and intends to comply with his continuing obligations
under this Agreement, including, but not limited to, the terms of the
Confidentiality, Non-Solicitation and Non-Compete Agreement.  To the
extent it is known or applicable at the time of such exit interview, Executive
shall also provide the Employer with information concerning Executive's
subsequent employer and the capacity in which Executive will be employed.
Executive's failure to comply shall be a material breach of this Agreement, for
which the Employer, in addition to any other civil remedy, may seek equitable
relief.

     

    
       

      
        
          	 	      
                  Executive
      Initials

                
	 	 
	 	 
	 	
                  ____________

                

        

      

       

    

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    Execution
Copy

    
 

    10.           Withholding.
All payments made to Executive shall be made net of any applicable withholding
for income taxes and Executive's share of FICA, FUTA or other employment taxes.
The Company shall withhold such amounts from such payments to the extent
required by applicable law and remit such amounts to the applicable governmental
authorities in accordance with applicable law.

    

    11.           Representations
of Executive.  Executive represents and warrants to NeoGenomics
that (a) nothing in his past legal and/or work and/or personal experiences,
which if became broadly known in the marketplace, would impair his ability to
serve as the Chief Executive Officer of a publicly-traded company or materially
damage his credibility with public shareholders; (b) there are no restrictions,
agreements, or understandings whatsoever to which he  is a party which
would prevent or make unlawful his execution of this Agreement or employment
hereunder, (c) Executive’s execution of this Agreement and employment hereunder
shall not constitute a breach of any contract, agreement or understanding, oral
or written, to which he is a party or by which he is bound, (d) Executive is
free and able to execute this Agreement and to continue  employment
with NeoGenomics, and (e) Executive has not used and will not use confidential
information or trade secrets belonging to any prior employers to perform
services for the Company.

    

    12.            Effect of
Partial Invalidity.  The invalidity of any portion of this
Agreement shall not affect the validity of any other provision.  In
the event that any provision of this Agreement is held to be invalid, the
parties agree that the remaining provisions shall remain in full force and
effect.

    

    13.           Entire
Agreement.  This Agreement, together with the other documents
referenced herein, reflects the complete agreement between the parties regarding
the subject matter identified herein and shall supersede all other previous
agreements, either oral or written, between the parties. The parties stipulate
that neither of them, nor any person acting on their behalf has made any
representations except as are specifically set forth in this Agreement and each
of the parties acknowledges that it or he has not relied upon any representation
of any third party in executing this Agreement, but rather have relied
exclusively on it or his own judgment in entering into this
Agreement.

    

    14.           Assignment.  Employer
may assign its interest and rights under this Agreement at its sole discretion
and without approval of Executive to a successor in interest by the Employer’s
merger, consolidation or other form of business combination with or into a third
party where the Employer’s stockholders before such event do not control a
majority of the resulting business entity after such event.  All
rights and entitlements arising from this Agreement, including but not limited
to those protective covenants and prohibitions set forth in the Confidentiality,
Non-Solicitation and Non-Compete Agreement attached as Addendum A and
incorporated into this Agreement shall inure to the benefit of any purchaser,
assignor or transferee of this Agreement and shall continue to be enforceable to
the extent allowable under applicable law.  Neither this Agreement,
nor the employment status conferred with its execution is assignable or subject
to transfer in any manner by Executive.

    

    15.           Notices.  All
notices, requests, demands, and other communications shall be in writing and
shall be given by registered or certified mail, postage prepaid, a) if to the
Employer, at the Employer’s then current headquarters location, and b) if to
Executive, at the most recent address on file with the Company for Executive or
to such subsequent addresses as either party shall so designate in writing to
the other party.

    
       

       

      
        
          	 	      
                  Executive
      Initials

                
	 	 
	 	 
	 	
                  ____________

                

        

      

       

    

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    Execution
Copy

    
 

    16.           Remedies.  If
any action at law, equity or in arbitration, including an action for declaratory
relief, is brought to enforce or interpret the provisions of this Agreement, the
prevailing party may, if the court or arbitrator hearing the dispute, so
determines, have its reasonable attorneys’ fees and costs of enforcement
recouped from the non-prevailing party.

    

    17.           Amendment/Waiver.  No
waiver, modification, amendment or change of any term of this Agreement shall be
effective unless it is in a written agreement signed by both
parties.  No waiver by the Employer of any breach or threatened breach
of this Agreement shall be construed as a waiver of any subsequent breach unless
it so provides by its terms.

    

    18.           Governing
Law, Venue and Jurisdiction.  This Agreement and all
transactions contemplated by this Agreement shall be governed by, construed, and
enforced in accordance with the laws of the State of Florida without regard to
any conflicts of laws, statutes, rules, regulations or
ordinances.  Executive consents to personal jurisdiction and venue in
the Circuit Court in and for Lee County, Florida regarding any action arising
under the terms of this Agreement and any and all other disputes between
Executive and Employer.

    

    19.           Arbitration. 
Any and all controversies and disputes between Executive and Employer arising
from this Agreement or regarding any other matter whatsoever shall be submitted
to arbitration before a single unbiased arbitrator skilled in arbitrating such
disputes under the American Arbitration Association, utilizing its Commercial
Rules.  Any arbitration action brought pursuant to this section shall
be heard in Fort Myers, Lee County, Florida.  The Circuit Court in and
for Lee County, Florida shall have concurrent jurisdiction with any arbitration
panel for the purpose of entering temporary and permanent injunctive relief, but
only with respect to any alleged breach of the Confidentiality, Non-Solicitation
and Non-Compete Agreement.

    

    20.           Headings.  The
titles to the sections of this Agreement are solely for the convenience of the
parties and shall not affect in any way the meaning or interpretation of this
Agreement.

    

    21.           Miscellaneous
Terms.  The parties to this Agreement declare and represent
that:

    

    
      	
               
      

            	
              a.

            	
              They
      have read and understand this
Agreement;

            

    

    

    
      	
               
      

            	
              b.

            	
              They
      have been given the opportunity to consult with an attorney if they so
      desire;

            

    

    

    
      	
               
      

            	
              c.

            	
              They
      intend to be legally bound by the promises set forth in this Agreement and
      enter into it freely, without duress or
  coercion;

            

    

    

    
      	
               
      

            	
              d.

            	
              They
      have retained signed copies of this Agreement for their records;
      and

            

    

    

    
      	
               
      

            	
              e.

            	
              The
      rights, responsibilities and duties of the parties hereto, and the
      covenants and agreements contained herein, shall continue to bind the
      parties and shall continue in full force and effect until each and every
      obligation of the parties under this Agreement has been
      performed.

            

    

    

    22.           Counterparts.  This Agreement
may be executed in counterparts and by facsimile, or by pdf, each of which shall
be deemed an original for all intents and purposes.

    

    Signatures
appear on the following page.

    
       

      
        
          	 	      
                  Executive
      Initials

                
	 	 
	 	 
	 	
                  ____________

                

        

      

       

    

    
      
         

      

      
        8

        
          

        

      

      
         

      

      
        Execution
Copy

      

       

       

    

    IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date first
written above.

    

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                
                                  	
                                           

                                        	 
      
	 
      	
                                          NEOGENOMICS,
      INC., a Nevada Corporation

                                        
	 
      	 
      
	 
      	
                                          By:

                                        	/s/ Robert Gasparini
	 	 	 
	 	      
                                          Name:
      

                                        	/s/ Robert Gasparini
	 	 	 
	 	      
                                          Title:
      

                                        	President
	 
      	 
      
	 
      	 
      
	 
      	 
      
	 
      	 
      
	 
      	 
      
	 
      	
                                          EXECUTIVE:

                                        
	 
      	 
      
	 
      	
                                          /s/
      Douglas M. VanOort

                                        
	 
      	
                                          Douglas
      M. VanOort

                                        

                                   

                                   

                                   

                                  
                                    
                                      	 	      
                                              Executive
      Initials

                                            
	 	 
	 	 
	 	
                                              ____________

                                            

                                    

                                  

                                

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

     

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

    
      Execution
Copy

       

    

     

    Addendum
A

    

    Form
of Confidentiality, Non-Compete and Non-Solicitation Agreement

     

    
 

     

     

     

     

     

    
       

      
        
          	 	      
                  Executive
      Initials

                
	 	 
	 	 
	 	
                  ____________

                

        

      

       

    

    
      
         

      

      
        10Execution
Copy

    

     

    NEOGENOMICS,
INC.

    

    SUBSCRIPTION
AGREEMENT

    

    This
Subscription Agreement (the “Agreement”) is between NeoGenomics, Inc., a Nevada
corporation (the “Company”), and Douglas M. VanOort Living Trust, a trust whose
address is set forth on the signature block hereto (the
“Subscriber”).

    

    WHEREAS,
the Company recently hired the beneficiary of the Subscriber as  the
Executive Chairman and Interim CEO of the Company and desires to allow the
Subscriber to purchase shares of common stock, par value $0.001 per share (the
“Common Stock”), of the Company in an exempt, limited private offering under
Rule 506 of Regulation D (“Reg. D”) promulgated under the Securities Act of
1933, as amended (the “Securities Act”), on the terms and conditions hereinafter
set forth, and the Subscriber desires to acquire the number of shares of the
Common Stock as specifically set forth on the signature page
hereof;

    

    NOW,
THEREFORE, for and in consideration of the agreements hereinafter set forth, the
parties agree as follows:

    

    1.           Subscription For
Shares.  Subject to the terms and conditions hereinafter set
forth, the Subscriber hereby subscribes for and agrees to purchase from the
Company such number of shares of Common Stock as set forth upon the signature
page hereof (the “Subscription Shares”) at a price payable in cash equal to
$0.80 per Subscription Share, and the Company agrees to sell and issue such
Subscription Shares to the Subscriber for such purchase
price.   This Agreement shall be effective on the later of the
date of (i) acceptance by the Company or (ii) the receipt by the Company of
payment in full for the Subscription Shares (the “Effective
Date”).  The certificate for the Subscription Shares shall be
delivered by the Company within five days following the Effective
Date.   The Subscriber agrees that he will not, for a period of
Seven Hundred Thirty (730) days from the Effective Date (the “Lock-up Period”),
directly or indirectly, sell, transfer, assign or hypothecate any of the
Subscription Shares except for the transfer of up to an aggregate of fifty
percent (50%) of the Subscription Shares to (i) his spouse and/or his children
or any trust set up for the benefit of his spouse and/or children or (ii) any
entity that is an Affiliate of the Subscriber; provided that, any such
transferees shall be bound by the restrictions set forth in this Agreement and,
to the extent requested by the Company,  shall agree in writing to be
bound  by the provisions of this Agreement by executing a joinder in a
form reasonably acceptable to the Company.  Notwithstanding the
foregoing, if the Subscriber’s employment with the Company under that certain
Employment Agreement, dated March 16, 2009, is terminated by the Company for any
reason prior to the expiration of the Lock-up Period, then such Lock-up Period
shall be deemed to have expired as well.  For purposes of this
Agreement, such permitted transferees are referred to herein as “Permitted
Transferees”.   For purposes of this Agreement, “Affiliate” of a
Person (as defined below) means any other Person that, directly or indirectly
through one or more intermediaries, controls or is controlled by or is under
common control with the first Person.  For purposes of this Agreement,
“Person” means an individual or corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability company, joint
stock company, government (or an agency or subdivision thereof) or other entity
of any kind.

    

    
      	
               
      

            	
              2.

            	
              Acknowledgements,
      Agreements, Representations and Covenants of
      Subscriber.

            

    

    

    2.1           (a)           The
Subscriber acknowledges that a purchase of the Subscription Shares involves a
high degree of risk in that (i) the Company is highly
speculative;  (ii) the investment is illiquid; and (iii)
transferability of the Subscription Shares is extremely limited.

    

    (b)           The
Subscriber represents that he is an “accredited investor” within the meaning of
Rule 501(a) of Reg. D.

     

    
      
         

      

      
        - 1
-

        
          

        

      

      
         

      

      
        Execution
Copy

      

       

       

    

    (c)           The
Subscriber represents and warrants (i) that he has been furnished by the Company
during the course of evaluating his interest in this transaction with all
information regarding the Company which he had requested or desired to know;
(ii) that all documents which could be reasonably provided have been made
available for his inspection and review; (iii) that he has been afforded the
opportunity to ask questions of and receive answers from duly authorized
officers or other representatives of the Company concerning the terms and
conditions of the offering; (iv) that he has read in its entirety the Company’s
most recent Securities and Exchange Commission filings including Amendment No.1
to Form S-1 Registration Statement filed January 22, 2009 and related prospectus
filed on March 11, 2009 which includes the Company’s risk factors, and fully
understands the information contained therein; and (v) that he understands those
risk factors associated with an investment in the Subscription
Shares.

    

    (d)           The
Subscriber acknowledges that the purchase price for the Subscription Shares has
been established based on a valuation for the Company which bears no
relationship to the assets or book value of the Company, or any other customary
valuation criteria.

    

     (e)           The
Subscriber represents (i) that he has not been the subject of any general
solicitation by the Company, and (ii) that he knows of no general solicitation,
including any general advertising, by the Company in connection with the sale of
the Subscription Shares.

    

    (f)           The
Subscriber acknowledges that this offering of Subscription Shares may involve
tax consequences and that he has received no opinions or statements from the
Company in respect of same.  The Subscriber further acknowledges that
he must retain his own professional advisors to evaluate the tax and other
consequences of an investment in the Subscription Shares.

    

    2.2           (a)           The
Subscriber acknowledges that the Subscription Shares have not been registered
under the Securities Act, or the securities laws of any individual states, that
the Subscription Shares are being purchased for investment purposes and not with
a view to distribution or resale, nor with the intention of selling,
transferring or otherwise disposing of all or any part of such Subscription
Shares for any particular price, or at any particular time, or upon the
happening of any particular event or circumstances, except in full compliance
with all applicable provisions of the Securities Act, the rules and regulations
promulgated by the  Securities and Exchange Commission (the “SEC”)
thereunder or in connection therewith, and applicable state securities
laws.  The Subscriber further acknowledges that the Subscription
Shares must be held indefinitely unless they become registered under the
Securities Act, or an exemption from such registration is available, and an
opinion of counsel is furnished stating that registration is not required under
the Securities Act or such state securities laws.

    

    (b)           The
Subscriber is aware and understands that availability of the claimed exemption
from registration under the Securities Act  depends, in part, upon his
investment intention.  In this connection, the Subscriber is further
aware and understands that it is the position of the SEC that the statutory
basis for such exemption would not be present if his representation merely meant
that his present intention was to hold such securities for a short period, such
as the capital gains period under any tax statutes, for a deferred sale, for a
market rise, assuming that a market is maintained, or for any other fixed
period.  The Subscriber is further aware and understands that, in the
view of the SEC, a purchase now with an intent to resell (notwithstanding any
registration rights granted in connection with such Subscription Shares) would
represent a purchase with an intent inconsistent with his representation to the
Company contained herein, and the SEC would likely regard such a sale or
disposition as a deferred sale to which such exemptions are not
available.

    

    
      
         

      

      
        - 2
-

        
          

        

      

      
         

      

      
        Execution
Copy

      

       

       

    

    (c)           The
Subscriber understands that there is currently a very limited public market for
the Subscription Shares.  The Subscriber understands that the
Subscription Shares may only be disposed of pursuant to an effective
registration statement under the Securities Act or pursuant to an available
exemption from the registration requirements of the Securities Act, and in
compliance with any applicable state securities laws.   The
Subscriber further understands that Rule 144 (the “Rule”) promulgated under the
Securities Act requires, among other conditions, a holding period prior to the
resale (in limited amounts) of securities acquired in a non-public offering
without having to satisfy the registration requirements under the Securities
Act.   The Subscriber further understands and hereby acknowledges
that, unless and until the Subscription Shares are registered, any determination
to allow the Subscription Shares to be transferred out of the Subscriber’s name
shall be within the exclusive discretion of the Company, and shall only be
permitted to the extent that an opinion of counsel to the Company has been
obtained to the effect that neither the sale nor the proposed transfer would
result in a violation of the Securities Act or of the applicable securities laws
of any state or other jurisdiction.

    

    (d)           The
Subscriber acknowledges that the certificates to be issued representing the
Subscription Shares may bear a legend containing the following or similar
words:

    

    “THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR ANY OTHER SECURITIES
LAWS.  THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND
NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND MAY NOT BE TRANSFERRED, SOLD OR
OTHERWISE DISPOSED OF, OR OFFERED FOR TRANSFER, SALE OR OTHER DISPOSITION IN THE
ABSENCE OF (i) AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER THE
ACT, AND ANY OTHER APPLICABLE SECURITIES LAWS, OR (ii) THE AVAILABILITY OF AN
EXEMPTION FROM REGISTRATION UNDER THE ACT AND ANY OTHER APPLICABLE SECURITIES
LAWS AS EVIDENCED BY AN OPINION OF COUNSEL TO THE COMPANY”.

    

    2.3           The
Subscriber agrees to indemnify and hold harmless the Company,
and  each of its officers, directors, agents and attorneys against any
and all losses, claims, demands, liabilities and expenses incurred by the
Company and/or any such individual in connection with the defending or
investigating of any claims or liabilities, including reasonable legal or other
expenses as such are incurred and whether or not resulting in any liability to
the Company or such individual, to which any such indemnified party may become
subject under the Securities Act, under any other statute, at common law or
otherwise, insofar as such losses, claims, demands, liabilities and expenses (a)
arise out of or are based upon any untrue representation or other
statement  of a material fact contained in this Subscription
Agreement, or (b) arise out of or are based upon any breach by the Subscriber of
any representation, warranty, agreement or covenant contained
herein.

    

    2.4           The
Subscriber represents that the address furnished at the end of this Subscription
Agreement is the address of Subscriber’s principal residence.

    

    2.5           The
Subscriber acknowledges that at such time, if ever, as any of the Subscription
Shares are registered, sales of such Subscription Shares will be subject to
federal, state and other applicable securities laws, including those which may
require that such securities be sold through a registered broker-dealer or in
reliance upon an exemption from registration, and the Subscriber agrees and
covenants to comply with all such applicable laws.

    

    2.6           The
Subscriber agrees and covenants to execute and deliver all such further
documents, agreements, and instruments, and take such other and further action,
as may be reasonably requested by the Company to carry out the purposes and
intent of, and any legal requirements associated with, this Subscription
Agreement.

    

    
      
         

      

      
        - 3
-

        
          

        

      

      
         

      

      
        Execution
Copy

      

       

       

    

    3.           Representations, Agreements,
and Covenants of the Company.

    

    3.1           
The Company hereby represents and warrants to the Subscriber as of the date
hereof as follows:

    

    (a)           The
Company is a corporation duly organized and existing under the laws of the State
of Nevada, and has the power to conduct the business which it
conducts.

    

    (b)           The
acceptance, execution, and delivery of this Subscription Agreement by the
Company shall have been duly approved by the board of directors of the Company,
and all other actions required to authorize and effect the offer and sale of the
Subscription Shares shall have been duly taken and approved.

    

    (c)           Upon
issuance, the Subscription Shares shall be fully paid and
non-assessable.

    

    3.2           The
Company is not subject to any pre-emptive rights or any other contractual
obligations that would preclude or interfere with the sale of the Subscription
Shares.

    

    3.3           As
of the date hereof, the Company has (i) 100,000,000 shares of Common Stock
authorized, of which 32,131,021 are issued and outstanding prior to taking into
consideration the Subscription Shares, (ii) 10,000,000 shares of Preferred Stock
authorized, of which none are outstanding, and (iii)  outstanding warrants
to purchase 5,837,838 shares of Common Stock.  The Company further
represents  that as of December 31, 2009, it had outstanding options
to purchase 3,755,126 shares of Common Stock and that it does not believe that
such number of outstanding options has changed materially since December 31,
2008.

    

    4.           Piggyback
Registration.

     

     4.1           Following
the expiration of the Lock-up Period, until all Subscription Shares (the
“Registrable Securities”) held by the Subscriber and any Permitted Transferees
(the “Stockholders”) have been sold or may be sold without any restrictions
pursuant to Rule 144 promulgated under the Securities Act, if (but without any
obligation to do so) the Company proposes to register any of its Common Stock
under the Securities Act  in connection with the public offering of
such securities by the Company solely for cash (other than a registration on
Form S-8 (or similar or successor form) relating solely to the sale of
securities to participants in a Company stock plan or to other compensatory
arrangements to the extent includable on Form S-8 (or similar or successor
form), or a registration on Form S-4 (or similar or successor form)), the
Company shall, at such time, promptly give each Stockholder that then holds
Registrable Securities written notice of such registration.  Upon the
written request of any such Stockholders or any other party that may have
piggyback registration rights with the Company received by the Company within
ten (10) business days after mailing of such notice by the Company in accordance
with this Section
4(a) (the “Electing Holders”),
the Company shall (subject to, among other things, limitations imposed by the
Securities and Exchange Commission or federal securities laws and regulations)
use its commercially reasonable efforts to include in such registration all of
such Registrable Securities that are specified in such
request.  Notwithstanding the foregoing, the Company shall not be
required to register any Registrable Securities that are eligible for resale
pursuant to Rule 144 promulgated under the Securities Act or that are the
subject of a then effective registration statement.  If the
registration involves an underwritten offering to the public, all Electing
Holders must sell their Registrable Securities to the underwriters selected by
the Company on the same terms and conditions as apply to the Company or other
selling stockholders.  If, at any time after giving notice of the
Company’s intention to register any securities pursuant to this Section 4(a) and
prior to the effective date of the registration statement filed in connection
with such registration, the Company shall determine for any reason not to
register such securities, the Company shall give written notice to all holders
of Registrable Securities and, thereupon, shall be relieved of its obligation to
register any Registrable Securities in connection with such
registration.  The Company shall have no obligation to make any
offering of its securities, or to complete an offering of its securities that it
proposes to make.

    

    
      
         

      

      
        - 4
-

        
          

        

      

      
         

      

      
        Execution
Copy

      

       

       

    

    4.2 If such registration involves an
underwritten offering to the public, if the managing underwriter of the
underwritten offering shall inform the Company by letter of the underwriter’s
opinion that the number of Registrable Securities requested to be included in
such registration would, in its opinion, materially adversely affect such
offering, including the price at which such securities can be sold, and the
Company has so advised the Electing Holders in writing, then the Company shall
include in such registration, to the extent of the number that the Company is so
advised can be sold in (or during the time of) such offering, (i) first, all
securities proposed by the Company to be sold for its own account, then (ii)
such Registrable Securities requested to be included by the Electing Holders,
allocated pro rata among such Electing Holders in proportion, as nearly as
practicable, to the respective amounts of such securities requested to be
included in such registration.

    

    4.3 Each Electing Holder agrees that,
upon receipt of any notice from the Company of the happening of a Specified
Event (as defined below) such Electing Holder will immediately discontinue
disposition of Registrable Securities pursuant to any registration statement
covering such Registrable Securities until such Electing Holder’s receipt of
copies of a supplemented or amended prospectus (which the Company shall promptly
prepare following the happening of a Specified Event) or receipt of notice that
no supplement or amendment is required.  For purposes of this
Agreement, “Specified Event” means (i) the Securities and Exchange Commission
issues any stop order suspending the effectiveness of any registration statement
or initiates any proceedings for that purpose; (ii) the Company receives notice
of any suspension of the qualification or exemption from qualification of any
Registrable Securities for sale in any jurisdiction, or the initiation or threat
of any proceeding for such purpose; or (iii) the financial statements included
in any registration statement become ineligible for inclusion therein or any
statement made in any registration statement or related prospectus or any
document incorporated or deemed to be incorporated therein by reference is
untrue in any material respect or any revision to a registration statement,
related prospectus or other document is required so that it will not contain any
untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading.

    

    4.4           Each
Electing Holder covenants and agrees that it will comply with the prospectus
delivery requirements of the Securities Act as applicable to it or an exemption
therefrom in connection with sales of Registrable Securities pursuant to a
registration statement.

    

    4.5           Each
Electing Holder shall furnish to the Company such information regarding such
holder and the distribution proposed by such holder as the Company may
reasonably request in writing and as shall be reasonably required in connection
with any registration referred to in this Section 4.

    

    5.           Miscellaneous.

    

    5.1           Any
notice, service of process, or other communication given hereunder shall be
deemed sufficient if in writing and sent by registered or certified mail, return
receipt requested, addressed to the Company at 12701 Commonwealth Drive, Suite
5, Fort Meyers, FL 33913, and to the Subscriber at his address indicated on the
last page of this Subscription Agreement.  Notices shall be deemed to
have been given on the date of mailing, except notices of change of address,
which shall be deemed to have been given when received.  Either party
may change its address for purposes hereof at any time or from time to time by
providing notice in writing to the other party in accordance herewith, and any
such newly designated address shall thereafter serve for purposes hereof in lieu
of the address stated herein.

    

    
      
         

      

      
        - 5
-

        
          

        

      

      
         

      

      
        Execution
Copy

      

       

       

    

    5.2           This
Subscription Agreement shall not be changed, modified, or amended except through
a writing signed by both the Company and the Subscriber.

    

    5.3           This
Subscription Agreement shall be binding upon and inure to the benefit of the
parties hereto and to their respective heirs, legal representatives, successors,
and/or assigns.   This Subscription Agreement sets forth the
entire agreement and understanding between the parties as to the subject matter
hereof and supersedes all prior discussions, agreements, and understandings of
any and every nature between them.

    

    5.4           Notwithstanding
the place where this Subscription Agreement may have been executed by either
party, it is agreed that all the terms and provisions hereof shall be construed
in accordance with and governed by the laws of the State of Nevada without
regard to principles of conflicts of laws.  The parties hereby agree
that any dispute that may arise between them arising out of or in connection
with this Subscription Agreement shall be adjudicated before a court located in
Lee County, Florida  and they hereby submit to the exclusive
jurisdiction of the courts of the State of Florida located in Fort Myers,
Florida, and of the federal courts having jurisdiction in such district with
respect to any action or legal proceeding commenced by either party, and
irrevocably waive any objection they now or hereafter may have respecting the
venue of any such action or proceeding brought in such a court or respecting the
fact that such court is an inconvenient forum, relating to or arising out of
this Subscription Agreement or any acts or omissions relating to the sale of the
securities pursuant hereto.

    

    5.5           This
Subscription Agreement may be executed in counterparts.  Upon the
execution and delivery of this Subscription Agreement by the Subscriber, this
Subscription Agreement shall become a binding obligation of the Subscriber with
respect to the purchase of the Subscription Shares as herein provided, but shall
only be binding upon the Company if and when executed by the
Company.

    

    5.6           The
holding of any provision of this Subscription Agreement to be invalid or
unenforceable by a court of competent jurisdiction shall not affect any other
provision of this Subscription Agreement, which shall remain in full force and
effect.

    

    5.7           It
is agreed that a waiver by either party of a breach of any provision of this
Subscription Agreement shall not operate, or be construed, as a waiver of any
subsequent or continuing breach by that same party.

    

    IN
WITNESS WHEREOF, the parties have executed this Subscription Agreement as of the
day and year set forth in each case below.

    

    
      
        
          
            
              
                
                  
                    
                      
                        	
                                Signature
      of Subscriber or Representative

                              	 	      
                                Subscription
      Accepted:

                              	 
	
                                DOUGLAS
      M. VANOORT LIVING TRUST

                              	 	      
                                NEOGENOMICS,
      INC.

                              	 
	 
      	 
      	 	      
                                - A
      Nevada Corporation -

                              	 
	 
      	 
      	
                                 

                              	 
      	 
      	 
	
                                /s/
      Douglas M. VanOort

                              	 
      	      
                                By:
      

                              	/s/Robert P. Gasparini	 
	
                                Name:

                              	
                                Douglas
      M. VanOort

                              	 	
                                Name:

                              	      
                                Robert
      P. Gasparini

                              	 
	
                                Title:

                              	
                                Trustee

                              	
                                 

                              	
                                Title:

                              	
                                President

                              	 
	
                                Date:

                              	
                                March
      16, 2009

                              	
                                 

                              	
                                Date:

                              	
                                March
      16, 2009

                              	 

                      

                    

                  

                

              

            

          

        

      

    

    

    
      	
              Address:

            	
              3275
      Regatta Road

            

    Naples,
FL 34103

    

    Total
Number of Common Shares Subscribed For:  625,000 (for a gross
purchase price of $500,000)

     

    
      
         

      

      
        - 6
-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}]]